Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
JAMA Neurology · 01.02.2023 · 80 (2) · 188
DOI: 10.1001/jamaneurol.2022.4485 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JAMA Neurology, erschienen am 01.02.2023. Verfasst von Joseph Therriault und 32 weiteren Autor:innen. Beteiligte Einrichtung: Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 286-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR.
Abstract (Originalsprache)
Importance The recent proliferation of phosphorylated tau (p-tau) biomarkers has raised questions about their preferential association with the hallmark pathologies of Alzheimer disease (AD): amyloid-β plaques and tau neurofibrillary tangles.
Objective
To determine whether cerebrospinal fluid (CSF) and plasma p-tau biomarkers preferentially reflect cerebral β-amyloidosis or neurofibrillary tangle aggregation measured with positron emission tomography (PET). Design, Setting, and Participants This was a cross-sectional study of 2 observational cohorts: the Translational Biomarkers in Aging and Dementia (TRIAD) study, with data collected between October 2017 and August 2021, and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), with data collected between September 2015 and November 2019. TRIAD was a single-center study, and ADNI was a multicenter study. Two independent subsamples were derived from TRIAD. The first TRIAD subsample comprised individuals assessed with CSF p-tau (p-tau 181 , p-tau 217 , p-tau 231 , p-tau 235 ), [ 18 F]AZD4694 amyloid PET, and [ 18 F]MK6240 tau PET. The second TRIAD subsample included individuals assessed with plasma p-tau (p-tau 181 , p-tau 217 , p-tau 231 ), [ 18 F]AZD4694 amyloid PET, and [ 18 F]MK6240 tau PET. An independent cohort from ADNI comprised individuals assessed with CSF p-tau 181 , [ 18 F]florbetapir PET, and [ 18 F]flortaucipir PET. Participants were included based on the availability of p-tau and PET biomarker assessments collected within 9 months of each other. Exclusion criteria were a history of head trauma or magnetic resonance imaging/PET safety contraindications. No participants who met eligibility criteria were excluded. Exposures Amyloid PET, tau PET, and CSF and plasma assessments of p-tau measured with single molecule array (Simoa) assay or enzyme-linked immunosorbent assay. Main Outcomes and Measures Associations between p-tau biomarkers with amyloid PET and tau PET.
Results
A total of 609 participants (mean [SD] age, 66.9 [13.6] years; 347 female [57%]; 262 male [43%]) were included in the study. For all 4 phosphorylation sites assessed in CSF, p-tau was significantly more closely associated with amyloid-PET values than tau-PET values (p-tau 181 difference, 13%; 95% CI, 3%-22%; P = .006; p-tau 217 difference, 11%; 95% CI, 3%-20%; P = .003; p-tau 231 difference, 15%; 95% CI, 5%-22%; P < .001; p-tau 235 difference, 9%; 95% CI, 1%-19%; P = .02) . These results were replicated with plasma p-tau 181 (difference, 11%; 95% CI, 1%-22%; P = .02), p-tau 217 (difference, 9%; 95% CI, 1%-19%; P = .02), p-tau 231 (difference, 13%; 95% CI, 3%-24%; P = .009), and CSF p-tau 181 (difference, 9%; 95% CI, 1%-21%; P = .02) in independent cohorts. Conclusions and Relevance Results of this cross-sectional study of 2 observational cohorts suggest that the p-tau abnormality as an early event in AD pathogenesis was associated with amyloid-β accumulation and highlights the need for careful interpretation of p-tau biomarkers in the context of the amyloid/tau/neurodegeneration, or A/T/(N), framework.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Montreal, Quebec, Canada.
- Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
- Erasmus Medical Center, Erasmus University Rotterdam, Rotterdam, the Netherlands.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
- Wallenberg Centre for Molecular Medicine, University of Gothenburg, Gothenburg, Sweden.
- King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, United Kingdom.
Förderung
- CIHR
Zitieren
APA
Therriault, J., Vermeiren, M., Servaes, S., Tissot, C., Ashton, N. J., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Lussier, F. Z., Bezgin, G., Stevenson, J., Rahmouni, N., Kunach, P., Wang, Y. T., Fernandez-Arias, J., Socualaya, K. Q., Macedo, A. C., Ferrari-Souza, J. P., …, & Rosa-Neto, P. (2023). Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurology, 80(2), 188. https://doi.org/10.1001/jamaneurol.2022.4485
Vancouver
Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL, et al. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurology. 2023;80(2):188. doi:10.1001/jamaneurol.2022.4485
BibTeX
@article{Therriault2023,
author = {Therriault, Joseph and Vermeiren, Marie and Servaes, Stijn and Tissot, Cécile and Ashton, Nicholas J and Benedet, Andréa Lessa and Karikari, Thomas K and Lantero-Rodriguez, Juan and Brum, Wagner S and Lussier, Firoza Z and Bezgin, Gleb and Stevenson, Jenna and Rahmouni, Nesrine and Kunach, Peter and Wang, Yi-Ting and Fernandez-Arias, Jaime and Socualaya, Kely Quispialaya and Macedo, Arthur C and Ferrari-Souza, João Pedro and Ferreira, Pâmela C L and Bellaver, Bruna and Leffa, Douglas T and Zimmer, Eduardo R and Vitali, Paolo and Soucy, Jean-Paul and Triana-Baltzer, Gallen and Kolb, Hartmuth C and Pascoal, Tharick A and Saha-Chaudhuri, Paramita and Gauthier, Serge and Zetterberg, Henrik and Blennow, Kaj and Rosa-Neto, Pedro},
title = {Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography},
journal = {JAMA Neurology},
year = {2023},
volume = {80},
number = {2},
pages = {188},
doi = {10.1001/jamaneurol.2022.4485}
}
EUVIMED